Our current finding that AMPK contributed to the early stages of the apoptotic response induced by Bcl-2 inhibition suggested that combining venetoclax to a pharmacological AMPK activator might potentiate the apoptotic response in AML. The gene discussed is PRKAA1; the disease is acute myeloid leukemia.